Celldex (CLDX) to Present Positive Barzolvolimab Phase 1b Study Data in Chronic Inducible Urticaria at Global Urticaria Forum 2022
Tweet Send to a Friend
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced new data from the Company’s open label Phase 1b clinical trial of barzolvolimab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
